Skip to main content

Table 2 Myocardial infarctions identified by the clinical events committee but not the site investigator

From: Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study

  Eastern Europe Latin America North America Western Europe Overall
Clinical scenario (n = 182) (n = 44) (n = 299) (n = 291) (n = 816)
Asymptomatic CK-MB elevation* 83 (46) 23 (52) 37 (12) 128 (44) 271 (33)
Ischemic event 89 (49) 12 (27) 48 (16) 68 (23) 217 (27)
Coronary artery bypass graft-related 6 (3) 6 (14) 138 (46) 52 (18) 202 (25)
PCI-related 2 (1) 1 (2) 62 (21) 22 (8) 87 (11)
Early myocardial infarction 1 (1) 0 (0.0) 3 (1) 3 (1) 7 (1)
Isolated electrocardiogram (Q waves)§ 1 (1) 1 (2) 5 (2) 4 (1) 11 (1)
Peri-death 0 (0) 1 (2) 1 (0.3) 4 (1) 6 (1)
Miscellaneous 0 (0) 0 (0) 5 (2) 10 (3) 15 (2)
  1. Data presented as n (%). CK-MB, CK-MB = creatine kinase-myocardial band; PCI, percutaneous coronary intervention. * No clinical symptoms or electrocardiography (ECG) evidence of ischemia. Clinical evidence of ischemia and ECG/cardiac enzyme evidence of infarction. Cardiac enzyme or ECG evidence of infarction < 24 hours after enrolment, different from the enrolment event. § Identified by systematic review of ECGs without clinical evidence of reinfarction. Myocardial infarction at the time of death with clinical, ECG, or cardiac enzyme evidence.